Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis
CONCLUSIONS: While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There is insufficient evidence to guide this therapy with regard to plausible adverse long-term outcomes. Further RCTs with direct comparisons between systemic corticosteroid treatments are needed to determine the optimal treatment approach, and these studies should be adequately powered to evaluate survival without major neurosensory disability.PMID:37650547 | DOI:10.1002/14651858.CD013730.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Susanne Hay Colleen Ovelman John Af Zupancic Lex W Doyle Wes Onland Menelaos Konstantinidis Prakeshkumar S Shah Roger Soll Source Type: research
More News: Brain | Bronchopulmonary Dysplasia | Cerebral Palsy | Clinical Trials | Corticosteroid Therapy | Databases & Libraries | Dexamethasone | Disability | General Medicine | Hydrocortisone | Men | Neurology | Respiratory Medicine | Study